Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers.

Cammack AJ, Atassi N, Hyman T, van den Berg LH, Harms M, Baloh RH, Brown RH, van Es MA, Veldink JH, de Vries BS, Rothstein JD, Drain C, Jockel-Balsarotti J, Malcolm A, Boodram S, Salter A, Wightman N, Yu H, Sherman AV, Esparza TJ, McKenna-Yasek D, Owegi MA, Douthwright C; Alzheimer's Disease Neuroimaging Initiative, McCampbell A, Ferguson T, Cruchaga C, Cudkowicz M, Miller TM.

Neurology. 2019 Oct 22;93(17):e1605-e1617. doi: 10.1212/WNL.0000000000008359. Epub 2019 Oct 2.

PMID:
31578300
2.

Comparison of three congruent patient-specific cell types for the modelling of a human genetic Schwann-cell disorder.

Mukherjee-Clavin B, Mi R, Kern B, Choi IY, Lim H, Oh Y, Lannon B, Kim KJ, Bell S, Hur JK, Hwang W, Che YH, Habib O, Baloh RH, Eggan K, Brandacher G, Hoke A, Studer L, Kim YJ, Lee G.

Nat Biomed Eng. 2019 Jul;3(7):571-582. doi: 10.1038/s41551-019-0381-8. Epub 2019 Apr 8.

3.

Restoring mitofusin balance prevents axonal degeneration in a Charcot-Marie-Tooth type 2A model.

Zhou Y, Carmona S, Muhammad AKMG, Bell S, Landeros J, Vazquez M, Ho R, Franco A, Lu B, Dorn GW 2nd, Wang S, Lutz CM, Baloh RH.

J Clin Invest. 2019 Mar 18;130:1756-1771. doi: 10.1172/JCI124194. eCollection 2019 Mar 18.

4.

Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials.

van den Berg LH, Sorenson E, Gronseth G, Macklin EA, Andrews J, Baloh RH, Benatar M, Berry JD, Chio A, Corcia P, Genge A, Gubitz AK, Lomen-Hoerth C, McDermott CJ, Pioro EP, Rosenfeld J, Silani V, Turner MR, Weber M, Brooks BR, Miller RG, Mitsumoto H; Airlie House ALS Clinical Trials Guidelines Group.

Neurology. 2019 Apr 2;92(14):e1610-e1623. doi: 10.1212/WNL.0000000000007242. Epub 2019 Mar 8.

5.

Inflammation in ALS/FTD pathogenesis.

McCauley ME, Baloh RH.

Acta Neuropathol. 2019 May;137(5):715-730. doi: 10.1007/s00401-018-1933-9. Epub 2018 Nov 21. Review.

6.

T-Cell-Intrinsic Receptor Interacting Protein 2 Regulates Pathogenic T Helper 17 Cell Differentiation.

Shimada K, Porritt RA, Markman JL, O'Rourke JG, Wakita D, Noval Rivas M, Ogawa C, Kozhaya L, Martins GA, Unutmaz D, Baloh RH, Crother TR, Chen S, Arditi M.

Immunity. 2018 Nov 20;49(5):873-885.e7. doi: 10.1016/j.immuni.2018.08.022. Epub 2018 Oct 23.

PMID:
30366765
7.

Stem cell transplantation for amyotrophic lateral sclerosis.

Baloh RH, Glass JD, Svendsen CN.

Curr Opin Neurol. 2018 Oct;31(5):655-661. doi: 10.1097/WCO.0000000000000598. Review.

PMID:
30080719
8.

MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A.

Rocha AG, Franco A, Krezel AM, Rumsey JM, Alberti JM, Knight WC, Biris N, Zacharioudakis E, Janetka JW, Baloh RH, Kitsis RN, Mochly-Rosen D, Townsend RR, Gavathiotis E, Dorn GW 2nd.

Science. 2018 Apr 20;360(6386):336-341. doi: 10.1126/science.aao1785.

9.

Palatal tremor as a presenting symptom of amyotrophic lateral sclerosis.

Maghzi AH, Sahai S, Zimnowodzki S, Baloh RH.

Neurology. 2018 Apr 24;90(17):801-802. doi: 10.1212/WNL.0000000000005363. Epub 2018 Mar 23. No abstract available.

10.

Genome-wide Analyses Identify KIF5A as a Novel ALS Gene.

Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R, Dominov JA, Kenna BJ, Nalls MA, Keagle P, Rivera AM, van Rheenen W, Murphy NA, van Vugt JJFA, Geiger JT, Van der Spek RA, Pliner HA, Shankaracharya, Smith BN, Marangi G, Topp SD, Abramzon Y, Gkazi AS, Eicher JD, Kenna A; ITALSGEN Consortium, Mora G, Calvo A, Mazzini L, Riva N, Mandrioli J, Caponnetto C, Battistini S, Volanti P, La Bella V, Conforti FL, Borghero G, Messina S, Simone IL, Trojsi F, Salvi F, Logullo FO, D'Alfonso S, Corrado L, Capasso M, Ferrucci L; Genomic Translation for ALS Care (GTAC) Consortium, Moreno CAM, Kamalakaran S, Goldstein DB; ALS Sequencing Consortium, Gitler AD, Harris T, Myers RM; NYGC ALS Consortium, Phatnani H, Musunuri RL, Evani US, Abhyankar A, Zody MC; Answer ALS Foundation, Kaye J, Finkbeiner S, Wyman SK, LeNail A, Lima L, Fraenkel E, Svendsen CN, Thompson LM, Van Eyk JE, Berry JD, Miller TM, Kolb SJ, Cudkowicz M, Baxi E; Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium, Benatar M, Taylor JP, Rampersaud E, Wu G, Wuu J; SLAGEN Consortium, Lauria G, Verde F, Fogh I, Tiloca C, Comi GP, Sorarù G, Cereda C; French ALS Consortium, Corcia P, Laaksovirta H, Myllykangas L, Jansson L, Valori M, Ealing J, Hamdalla H, Rollinson S, Pickering-Brown S, Orrell RW, Sidle KC, Malaspina A, Hardy J, Singleton AB, Johnson JO, Arepalli S, Sapp PC, McKenna-Yasek D, Polak M, Asress S, Al-Sarraj S, King A, Troakes C, Vance C, de Belleroche J, Baas F, Ten Asbroek ALMA, Muñoz-Blanco JL, Hernandez DG, Ding J, Gibbs JR, Scholz SW, Floeter MK, Campbell RH, Landi F, Bowser R, Pulst SM, Ravits JM, MacGowan DJL, Kirby J, Pioro EP, Pamphlett R, Broach J, Gerhard G, Dunckley TL, Brady CB, Kowall NW, Troncoso JC, Le Ber I, Mouzat K, Lumbroso S, Heiman-Patterson TD, Kamel F, Van Den Bosch L, Baloh RH, Strom TM, Meitinger T, Shatunov A, Van Eijk KR, de Carvalho M, Kooyman M, Middelkoop B, Moisse M, McLaughlin RL, Van Es MA, Weber M, Boylan KB, Van Blitterswijk M, Rademakers R, Morrison KE, Basak AN, Mora JS, Drory VE, Shaw PJ, Turner MR, Talbot K, Hardiman O, Williams KL, Fifita JA, Nicholson GA, Blair IP, Rouleau GA, Esteban-Pérez J, García-Redondo A, Al-Chalabi A; Project MinE ALS Sequencing Consortium, Rogaeva E, Zinman L, Ostrow LW, Maragakis NJ, Rothstein JD, Simmons Z, Cooper-Knock J, Brice A, Goutman SA, Feldman EL, Gibson SB, Taroni F, Ratti A, Gellera C, Van Damme P, Robberecht W, Fratta P, Sabatelli M, Lunetta C, Ludolph AC, Andersen PM, Weishaupt JH, Camu W, Trojanowski JQ, Van Deerlin VM, Brown RH Jr, van den Berg LH, Veldink JH, Harms MB, Glass JD, Stone DJ, Tienari P, Silani V, Chiò A, Shaw CE, Traynor BJ, Landers JE.

Neuron. 2018 Mar 21;97(6):1268-1283.e6. doi: 10.1016/j.neuron.2018.02.027.

11.

Cell transplantation strategies for acquired and inherited disorders of peripheral myelin.

Muhammad AKMG, Kim K, Epifantseva I, Aghamaleky-Sarvestany A, Simpkinson ME, Carmona S, Landeros J, Bell S, Svaren J, Baloh RH.

Ann Clin Transl Neurol. 2018 Jan 22;5(2):186-200. doi: 10.1002/acn3.517. eCollection 2018 Feb.

12.

Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia.

Lall D, Baloh RH.

J Clin Invest. 2017 Sep 1;127(9):3250-3258. doi: 10.1172/JCI90607. Epub 2017 Jul 24. Review.

13.

Patients with ALS show highly correlated progression rates in left and right limb muscles.

Rushton DJ, Andres PL, Allred P, Baloh RH, Svendsen CN.

Neurology. 2017 Jul 11;89(2):196-206. doi: 10.1212/WNL.0000000000004105. Epub 2017 Jun 9.

14.

ALS disrupts spinal motor neuron maturation and aging pathways within gene co-expression networks.

Ho R, Sances S, Gowing G, Amoroso MW, O'Rourke JG, Sahabian A, Wichterle H, Baloh RH, Sareen D, Svendsen CN.

Nat Neurosci. 2016 Sep;19(9):1256-67. doi: 10.1038/nn.4345. Epub 2016 Jul 18.

15.

C9orf72 is required for proper macrophage and microglial function in mice.

O'Rourke JG, Bogdanik L, Yáñez A, Lall D, Wolf AJ, Muhammad AK, Ho R, Carmona S, Vit JP, Zarrow J, Kim KJ, Bell S, Harms MB, Miller TM, Dangler CA, Underhill DM, Goodridge HS, Lutz CM, Baloh RH.

Science. 2016 Mar 18;351(6279):1324-9. doi: 10.1126/science.aaf1064.

16.

MORC2 mutations cause axonal Charcot-Marie-Tooth disease with pyramidal signs.

Albulym OM, Kennerson ML, Harms MB, Drew AP, Siddell AH, Auer-Grumbach M, Pestronk A, Connolly A, Baloh RH, Zuchner S, Reddel SW, Nicholson GA.

Ann Neurol. 2016 Mar;79(3):419-27. doi: 10.1002/ana.24575. Epub 2016 Jan 13.

17.

C9orf72 BAC Transgenic Mice Display Typical Pathologic Features of ALS/FTD.

O'Rourke JG, Bogdanik L, Muhammad AKMG, Gendron TF, Kim KJ, Austin A, Cady J, Liu EY, Zarrow J, Grant S, Ho R, Bell S, Carmona S, Simpkinson M, Lall D, Wu K, Daughrity L, Dickson DW, Harms MB, Petrucelli L, Lee EB, Lutz CM, Baloh RH.

Neuron. 2015 Dec 2;88(5):892-901. doi: 10.1016/j.neuron.2015.10.027.

18.

TDP-43 activates microglia through NF-κB and NLRP3 inflammasome.

Zhao W, Beers DR, Bell S, Wang J, Wen S, Baloh RH, Appel SH.

Exp Neurol. 2015 Nov;273:24-35. doi: 10.1016/j.expneurol.2015.07.019. Epub 2015 Jul 26.

PMID:
26222336
19.

Low-Dose Irradiation Enhances Gene Targeting in Human Pluripotent Stem Cells.

Hatada S, Subramanian A, Mandefro B, Ren S, Kim HW, Tang J, Funari V, Baloh RH, Sareen D, Arumugaswami V, Svendsen CN.

Stem Cells Transl Med. 2015 Sep;4(9):998-1010. doi: 10.5966/sctm.2015-0050. Epub 2015 Jul 16.

20.

TARDBP-Related Amyotrophic Lateral Sclerosis.

Harms MM, Miller TM, Baloh RH.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
2009 Apr 23 [updated 2015 Mar 12].

21.

Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways.

Cirulli ET, Lasseigne BN, Petrovski S, Sapp PC, Dion PA, Leblond CS, Couthouis J, Lu YF, Wang Q, Krueger BJ, Ren Z, Keebler J, Han Y, Levy SE, Boone BE, Wimbish JR, Waite LL, Jones AL, Carulli JP, Day-Williams AG, Staropoli JF, Xin WW, Chesi A, Raphael AR, McKenna-Yasek D, Cady J, Vianney de Jong JM, Kenna KP, Smith BN, Topp S, Miller J, Gkazi A; FALS Sequencing Consortium, Al-Chalabi A, van den Berg LH, Veldink J, Silani V, Ticozzi N, Shaw CE, Baloh RH, Appel S, Simpson E, Lagier-Tourenne C, Pulst SM, Gibson S, Trojanowski JQ, Elman L, McCluskey L, Grossman M, Shneider NA, Chung WK, Ravits JM, Glass JD, Sims KB, Van Deerlin VM, Maniatis T, Hayes SD, Ordureau A, Swarup S, Landers J, Baas F, Allen AS, Bedlack RS, Harper JW, Gitler AD, Rouleau GA, Brown R, Harms MB, Cooper GM, Harris T, Myers RM, Goldstein DB.

Science. 2015 Mar 27;347(6229):1436-41. doi: 10.1126/science.aaa3650. Epub 2015 Feb 19.

22.

Targeted sequencing and identification of genetic variants in sporadic inclusion body myositis.

Weihl CC, Baloh RH, Lee Y, Chou TF, Pittman SK, Lopate G, Allred P, Jockel-Balsarotti J, Pestronk A, Harms MB.

Neuromuscul Disord. 2015 Apr;25(4):289-96. doi: 10.1016/j.nmd.2014.12.009. Epub 2015 Jan 6.

23.

Novel mutations expand the clinical spectrum of DYNC1H1-associated spinal muscular atrophy.

Scoto M, Rossor AM, Harms MB, Cirak S, Calissano M, Robb S, Manzur AY, Martínez Arroyo A, Rodriguez Sanz A, Mansour S, Fallon P, Hadjikoumi I, Klein A, Yang M, De Visser M, Overweg-Plandsoen WC, Baas F, Taylor JP, Benatar M, Connolly AM, Al-Lozi MT, Nixon J, de Goede CG, Foley AR, Mcwilliam C, Pitt M, Sewry C, Phadke R, Hafezparast M, Chong WK, Mercuri E, Baloh RH, Reilly MM, Muntoni F.

Neurology. 2015 Feb 17;84(7):668-79. doi: 10.1212/WNL.0000000000001269. Epub 2015 Jan 21.

24.

Autophagic vacuolar pathology in desminopathies.

Weihl CC, Iyadurai S, Baloh RH, Pittman SK, Schmidt RE, Lopate G, Pestronk A, Harms MB.

Neuromuscul Disord. 2015 Mar;25(3):199-206. doi: 10.1016/j.nmd.2014.12.002. Epub 2014 Dec 12.

25.

Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known amyotrophic lateral sclerosis genes.

Cady J, Allred P, Bali T, Pestronk A, Goate A, Miller TM, Mitra RD, Ravits J, Harms MB, Baloh RH.

Ann Neurol. 2015 Jan;77(1):100-13. doi: 10.1002/ana.24306. Epub 2014 Nov 27.

26.

Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis.

Johnson JO, Pioro EP, Boehringer A, Chia R, Feit H, Renton AE, Pliner HA, Abramzon Y, Marangi G, Winborn BJ, Gibbs JR, Nalls MA, Morgan S, Shoai M, Hardy J, Pittman A, Orrell RW, Malaspina A, Sidle KC, Fratta P, Harms MB, Baloh RH, Pestronk A, Weihl CC, Rogaeva E, Zinman L, Drory VE, Borghero G, Mora G, Calvo A, Rothstein JD; ITALSGEN, Drepper C, Sendtner M, Singleton AB, Taylor JP, Cookson MR, Restagno G, Sabatelli M, Bowser R, Chiò A, Traynor BJ.

Nat Neurosci. 2014 May;17(5):664-666. doi: 10.1038/nn.3688. Epub 2014 Mar 30.

27.

TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis.

Cady J, Koval ED, Benitez BA, Zaidman C, Jockel-Balsarotti J, Allred P, Baloh RH, Ravits J, Simpson E, Appel SH, Pestronk A, Goate AM, Miller TM, Cruchaga C, Harms MB.

JAMA Neurol. 2014 Apr;71(4):449-53. doi: 10.1001/jamaneurol.2013.6237.

28.

A dominant mutation in FBXO38 causes distal spinal muscular atrophy with calf predominance.

Sumner CJ, d'Ydewalle C, Wooley J, Fawcett KA, Hernandez D, Gardiner AR, Kalmar B, Baloh RH, Gonzalez M, Züchner S, Stanescu HC, Kleta R, Mankodi A, Cornblath DR, Boylan KB, Reilly MM, Greensmith L, Singleton AB, Harms MB, Rossor AM, Houlden H.

Am J Hum Genet. 2013 Nov 7;93(5):976-83. doi: 10.1016/j.ajhg.2013.10.006. Epub 2013 Oct 24.

29.

Clinical neurogenetics: amyotrophic lateral sclerosis.

Harms MB, Baloh RH.

Neurol Clin. 2013 Nov;31(4):929-50. doi: 10.1016/j.ncl.2013.05.003. Review.

30.

Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration.

Lagier-Tourenne C, Baughn M, Rigo F, Sun S, Liu P, Li HR, Jiang J, Watt AT, Chun S, Katz M, Qiu J, Sun Y, Ling SC, Zhu Q, Polymenidou M, Drenner K, Artates JW, McAlonis-Downes M, Markmiller S, Hutt KR, Pizzo DP, Cady J, Harms MB, Baloh RH, Vandenberg SR, Yeo GW, Fu XD, Bennett CF, Cleveland DW, Ravits J.

Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):E4530-9. doi: 10.1073/pnas.1318835110. Epub 2013 Oct 29.

31.

Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion.

Sareen D, O'Rourke JG, Meera P, Muhammad AK, Grant S, Simpkinson M, Bell S, Carmona S, Ornelas L, Sahabian A, Gendron T, Petrucelli L, Baughn M, Ravits J, Harms MB, Rigo F, Bennett CF, Otis TS, Svendsen CN, Baloh RH.

Sci Transl Med. 2013 Oct 23;5(208):208ra149. doi: 10.1126/scitranslmed.3007529.

32.

Prion-like nuclear aggregation of TDP-43 during heat shock is regulated by HSP40/70 chaperones.

Udan-Johns M, Bengoechea R, Bell S, Shao J, Diamond MI, True HL, Weihl CC, Baloh RH.

Hum Mol Genet. 2014 Jan 1;23(1):157-70. doi: 10.1093/hmg/ddt408. Epub 2013 Aug 19.

33.

Dynein mutations associated with hereditary motor neuropathies impair mitochondrial morphology and function with age.

Eschbach J, Sinniger J, Bouitbir J, Fergani A, Schlagowski AI, Zoll J, Geny B, René F, Larmet Y, Marion V, Baloh RH, Harms MB, Shy ME, Messadeq N, Weydt P, Loeffler JP, Ludolph AC, Dupuis L.

Neurobiol Dis. 2013 Oct;58:220-30. doi: 10.1016/j.nbd.2013.05.015. Epub 2013 Jun 4.

34.

Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis.

Ravits J, Appel S, Baloh RH, Barohn R, Brooks BR, Elman L, Floeter MK, Henderson C, Lomen-Hoerth C, Macklis JD, McCluskey L, Mitsumoto H, Przedborski S, Rothstein J, Trojanowski JQ, van den Berg LH, Ringel S.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 May;14 Suppl 1:5-18. doi: 10.3109/21678421.2013.778548.

35.

Lack of C9ORF72 coding mutations supports a gain of function for repeat expansions in amyotrophic lateral sclerosis.

Harms MB, Cady J, Zaidman C, Cooper P, Bali T, Allred P, Cruchaga C, Baughn M, Libby RT, Pestronk A, Goate A, Ravits J, Baloh RH.

Neurobiol Aging. 2013 Sep;34(9):2234.e13-9. doi: 10.1016/j.neurobiolaging.2013.03.006. Epub 2013 Apr 16.

36.

How do the RNA-binding proteins TDP-43 and FUS relate to amyotrophic lateral sclerosis and frontotemporal degeneration, and to each other?

Baloh RH.

Curr Opin Neurol. 2012 Dec;25(6):701-7. doi: 10.1097/WCO.0b013e32835a269b. Review.

PMID:
23041957
37.

Mutations in the tail domain of DYNC1H1 cause dominant spinal muscular atrophy.

Harms MB, Ori-McKenney KM, Scoto M, Tuck EP, Bell S, Ma D, Masi S, Allred P, Al-Lozi M, Reilly MM, Miller LJ, Jani-Acsadi A, Pestronk A, Shy ME, Muntoni F, Vallee RB, Baloh RH.

Neurology. 2012 May 29;78(22):1714-20. doi: 10.1212/WNL.0b013e3182556c05. Epub 2012 Mar 28.

38.

Mitofusin2 mutations disrupt axonal mitochondrial positioning and promote axon degeneration.

Misko AL, Sasaki Y, Tuck E, Milbrandt J, Baloh RH.

J Neurosci. 2012 Mar 21;32(12):4145-55. doi: 10.1523/JNEUROSCI.6338-11.2012.

39.

Exome sequencing reveals DNAJB6 mutations in dominantly-inherited myopathy.

Harms MB, Sommerville RB, Allred P, Bell S, Ma D, Cooper P, Lopate G, Pestronk A, Weihl CC, Baloh RH.

Ann Neurol. 2012 Mar;71(3):407-16. doi: 10.1002/ana.22683. Epub 2012 Feb 14.

40.

Normal role of the low-molecular-weight neurofilament protein in mitochondrial dynamics and disruption in Charcot-Marie-Tooth disease.

Gentil BJ, Minotti S, Beange M, Baloh RH, Julien JP, Durham HD.

FASEB J. 2012 Mar;26(3):1194-203. doi: 10.1096/fj.11-196345. Epub 2011 Dec 12.

PMID:
22155564
41.

Sir-two-homolog 2 (Sirt2) modulates peripheral myelination through polarity protein Par-3/atypical protein kinase C (aPKC) signaling.

Beirowski B, Gustin J, Armour SM, Yamamoto H, Viader A, North BJ, Michán S, Baloh RH, Golden JP, Schmidt RE, Sinclair DA, Auwerx J, Milbrandt J.

Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):E952-61. doi: 10.1073/pnas.1104969108. Epub 2011 Sep 26.

42.

Endolysosomal sorting of ubiquitylated caveolin-1 is regulated by VCP and UBXD1 and impaired by VCP disease mutations.

Ritz D, Vuk M, Kirchner P, Bug M, Schütz S, Hayer A, Bremer S, Lusk C, Baloh RH, Lee H, Glatter T, Gstaiger M, Aebersold R, Weihl CC, Meyer H.

Nat Cell Biol. 2011 Aug 7;13(9):1116-23. doi: 10.1038/ncb2301.

43.

Anemia, paresthesias, and gait ataxia in a 57-year-old denture wearer.

Sommerville RB, Baloh RH.

Clin Chem. 2011 Aug;57(8):1103-6. doi: 10.1373/clinchem.2010.156364. No abstract available.

44.

TDP-43: the relationship between protein aggregation and neurodegeneration in amyotrophic lateral sclerosis and frontotemporal lobar degeneration.

Baloh RH.

FEBS J. 2011 Oct;278(19):3539-49. doi: 10.1111/j.1742-4658.2011.08256.x. Epub 2011 Aug 24. Review.

45.

Schwann cell mitochondrial metabolism supports long-term axonal survival and peripheral nerve function.

Viader A, Golden JP, Baloh RH, Schmidt RE, Hunter DA, Milbrandt J.

J Neurosci. 2011 Jul 13;31(28):10128-40. doi: 10.1523/JNEUROSCI.0884-11.2011.

46.

Genetic evaluation of inherited muscle diseases.

Baloh RH.

Continuum (Minneap Minn). 2011 Apr;17(2 Neurogenetics):280-93. doi: 10.1212/01.CON.0000396962.75069.2f.

PMID:
22810820
47.

Implications of the prion-related Q/N domains in TDP-43 and FUS.

Udan M, Baloh RH.

Prion. 2011 Jan-Mar;5(1):1-5. Epub 2011 Jan 1. Review.

48.

Novel GNE mutations in two phenotypically distinct HIBM2 patients.

Weihl CC, Miller SE, Zaidman CM, Pestronk A, Baloh RH, Al-Lozi M.

Neuromuscul Disord. 2011 Feb;21(2):102-5. doi: 10.1016/j.nmd.2010.11.002. Epub 2010 Dec 4.

49.

TDP-43-based animal models of neurodegeneration: new insights into ALS pathology and pathophysiology.

Wegorzewska I, Baloh RH.

Neurodegener Dis. 2011;8(4):262-74. doi: 10.1159/000321547. Epub 2010 Dec 3. Review.

50.

TDP-43 proteinopathy in familial motor neurone disease with TARDBP A315T mutation: a case report.

Cairns NJ, Perrin RJ, Schmidt RE, Gru A, Green KG, Carter D, Taylor-Reinwald L, Morris JC, Gitcho MA, Baloh RH.

Neuropathol Appl Neurobiol. 2010 Dec;36(7):673-9. doi: 10.1111/j.1365-2990.2010.01121.x. No abstract available.

Supplemental Content

Loading ...
Support Center